This paper is in the following e-collection/theme issue:

Pharmacovigilance (134) Adverse Drug Events Detection, Pharmacovigilance and Surveillance (156) Safety and Error Prevention in Health (202)

Published on in Vol 4, No 1 (2018): Jan-Mar

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/9282, first published .
Why Clinicians Don’t Report Adverse Drug Events: Qualitative Study

Why Clinicians Don’t Report Adverse Drug Events: Qualitative Study

Why Clinicians Don’t Report Adverse Drug Events: Qualitative Study

Authors of this article:

Corinne M Hohl1, 2, 3 Author Orcid Image ;   Serena S Small1, 4 Author Orcid Image ;   David Peddie1, 4 Author Orcid Image ;   Katherin Badke5 Author Orcid Image ;   Chantelle Bailey1, 2 Author Orcid Image ;   Ellen Balka1, 4 Author Orcid Image
Article Authors Cited by (41) Tweetations (42) Metrics

Journals

  1. Peddie D, Small S, Badke K, Bailey C, Balka E, Hohl C. Adverse Drug Event Reporting From Clinical Care: Mixed-Methods Analysis for a Minimum Required Dataset. JMIR Medical Informatics 2018;6(2):e10248 View
  2. Small S, Hohl C, Balka E. Organizational implications of implementing a new adverse drug event reporting system for care providers and integrating it with provincial health information systems. Healthcare Management Forum 2019;32(4):208 View
  3. Adenuga B, Kibuule D, Bamitale K, Rennie T. Effective integration of pharmacovigilance systems at public health facilities in resource-limited settings: A qualitative study. Research in Social and Administrative Pharmacy 2020;16(8):1111 View
  4. Abramova N, Hubbard J, Schertz J, Richter E. Safety of Follitropin Alfa/Lutropin Alfa for Stimulation of Follicular Development. Drug Safety 2019;42(3):453 View
  5. Güner M, Ekmekci P. Healthcare professionals’ pharmacovigilance knowledge and adverse drug reaction reporting behavior and factors determining the reporting rates. Journal of Drug Assessment 2019;8(1):13 View
  6. Graham M, Lucas C, Schneider J, Martin J, Hall W. Translational hurdles with cannabis medicines. Pharmacoepidemiology and Drug Safety 2020;29(10):1325 View
  7. Esquivel A, Mendoza G, Soria R, Velázquez N. Pharmacovigilance of Antivenoms in Toxicological Emergencies. Latin american journal of clinical sciences and medical technology 2019;1(1):8 View
  8. Hau J, Brasher P, Cragg A, Small S, Wickham M, Hohl C. Using ActionADE to create information continuity to reduce re-exposures to harmful medications: study protocol for a randomized controlled trial. Trials 2021;22(1) View
  9. Gras M, Gras-Champel V, Moragny J, Delaunay P, Laugier D, Masmoudi K, Liabeuf S. Impact of the COVID-19 outbreak on the reporting of adverse drug reactions associated with self-medication. Annales Pharmaceutiques Françaises 2021;79(5):522 View
  10. Kurteva S, Abrahamowicz M, Gomes T, Tamblyn R. Association of Opioid Consumption Profiles After Hospitalization With Risk of Adverse Health Care Events. JAMA Network Open 2021;4(5):e218782 View
  11. Mohiuddin A. Pharmacovigilance: Present Scenario and Future Goals. International Journal of Research Foundation of Hospital and Healthcare Administration 2018;6(2):91 View
  12. Zorzela L, Khamba B, Sparks E, Necyk C, Urichuk L, Katzman M, Koczerginski D, Chue P, Barnes J, Vohra S. Study of Natural Products Adverse Reactions (SONAR) in Adults with Mental Health Conditions: A Cross-Sectional Study. Drug Safety 2021;44(9):999 View
  13. Pittau B, Palla P, Pettinau F, Mastino A. A New Tool for an Awareness Plan Concerning Critical Issues, Needs and Attitudes of Citizens on the Use of Medicines. Healthcare 2021;9(11):1409 View
  14. Li R, Curtis K, Van C, Tabish Razi Zaidi S, Yeo C, Arun Kali C, Zaheen M, Therese Moujalli G, Castelino R. Why hospital-based healthcare professionals do not report adverse drug reactions: a mixed methods study using the Theoretical Domains Framework. European Journal of Clinical Pharmacology 2022;78(7):1165 View
  15. Fossouo Tagne J, Yakob R, Mcdonald R, Wickramasinghe N. Barriers and Facilitators Influencing Real-time and Digital-Based Reporting of Adverse Drug Reactions by Community Pharmacists: Qualitative Study Using the Task-Technology Fit Framework. Interactive Journal of Medical Research 2022;11(2):e40597 View
  16. George D, Palatty P. Pattern of adverse drug reactions to anticancer drugs at an apex hospital in south India: A retrospective study. Indian Journal of Pharmacy and Pharmacology 2022;9(3):191 View
  17. Fossouo Tagne J, Yakob R, Mcdonald R, Wickramasinghe N. Linking Activity Theory Within User-Centered Design: Novel Framework to Inform Design and Evaluation of Adverse Drug Reaction Reporting Systems in Pharmacy. JMIR Human Factors 2023;10:e43529 View
  18. Lim R, Thornton C, Stanek J, Ellett L, Thiessen M. Development of a Web-Based System to Report Medication-Related Adverse Effects: Design and Usability Study. JMIR Formative Research 2022;6(10):e37605 View
  19. Chan E, Small S, Wickham M, Cheng V, Balka E, Hohl C. The Utility of Different Data Standards to Document Adverse Drug Event Symptoms and Diagnoses: Mixed Methods Study. Journal of Medical Internet Research 2021;23(12):e27188 View
  20. Skutezky T, Small S, Peddie D, Balka E, Hohl C. Beliefs and perceptions of patient safety event reporting in a Canadian Emergency Department: a qualitative study. Canadian Journal of Emergency Medicine 2022;24(8):867 View
  21. Fossouo Tagne J, Yakob R, Dang T, Mcdonald R, Wickramasinghe N. Reporting, Monitoring, and Handling of Adverse Drug Reactions in Australia: Scoping Review. JMIR Public Health and Surveillance 2023;9:e40080 View
  22. Lambert B, Schiff G. RaDonda Vaught, medication safety, and the profession of pharmacy: Steps to improve safety and ensure justice. JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY 2022;5(9):981 View
  23. Tiemersma E, Ali I, Alemu A, Avong Y, Duga A, Elagbaje C, Isah A, Kay A, Mmbaga B, Mmari E, Mwamwitwa K, Nhlabatsi S, Sintayehu K, Arefayne A, Teferi M, Cobelens F, Härmark L. Baseline assessment of pharmacovigilance activities in four sub-Saharan African countries: a perspective on tuberculosis. BMC Health Services Research 2021;21(1) View
  24. Ali S, Curtain C, Bereznicki L, Salahudeen M. Actual drug-related harms in residential aged care facilities: a narrative review. Expert Opinion on Drug Safety 2022;21(8):1047 View
  25. Stone K, Scott K, Holroyd B, Lang E, Yee K, Taghizadeh N, Deol J, Dong K, Fanaeian J, Ghosh M, Low K, Ross M, Tanguay R, Faris P, Day N, McLane P. Buprenorphine/naloxone initiation and referral as a quality improvement intervention for patients who live with opioid use disorder: quantitative evaluation of provincial spread to 107 rural and urban Alberta emergency departments. Canadian Journal of Emergency Medicine 2023;25(7):598 View
  26. Zitu M, Zhang S, Owen D, Chiang C, Li L. Generalizability of machine learning methods in detecting adverse drug events from clinical narratives in electronic medical records. Frontiers in Pharmacology 2023;14 View
  27. Alloush R, van Lint J, van Marum R, Hermens W, Jessurun N. Hospital registration of adverse drug reactions in electronic health records: importance and contribution to pharmacovigilance. Expert Opinion on Drug Safety 2024;23(7):925 View
  28. Kurteva S, Abrahamowicz M, Beauchamp M, Tamblyn R. Comparison of Different Modeling Approaches for Prescription Opioid Use and Its Association With Adverse Events. American Journal of Epidemiology 2023;192(9):1592 View
  29. Fossouo Tagne J, Yakob R, Mcdonald R, Wickramasinghe N. A Web-Based Tool to Report Adverse Drug Reactions by Community Pharmacists in Australia: Usability Testing Study. JMIR Formative Research 2023;7:e48976 View
  30. Cragg A, Small S, Lau E, Rowe A, Lau A, Butcher K, Hohl C. Sharing Adverse Drug Event Reports Between Hospitals and Community Pharmacists to Inform Re-dispensing: An Analysis of Reports and Process Outcomes. Drug Safety 2023;46(11):1161 View
  31. Christ P, Dubrall D, Schmid M, Sachs B. Comparative Analysis of Information Provided in German Adverse Drug Reaction Reports Sent by Physicians, Pharmacists and Consumers. Drug Safety 2023;46(12):1363 View
  32. Lau E, Cragg A, Small S, Butcher K, Hohl C. Characterizing and Comparing Adverse Drug Events Documented in 2 Spontaneous Reporting Systems in the Lower Mainland of British Columbia, Canada: Retrospective Observational Study. JMIR Human Factors 2024;11:e52495 View
  33. Rapaić A, Milošević E, Todorović N, Janjić N, Lalić-Popović M, Milošević N. Suspected Hematuria: Adverse Effects of Rivaroxaban in Older Adult Treated for Atrial Fibrillation. Reports 2024;7(1):11 View
  34. Wickham M, McGrail K, Law M, Cragg A, Hohl C. Validating use of diagnostic codes in Canadian administrative data for identification of adverse drug events. British Journal of Clinical Pharmacology 2024;90(7):1688 View
  35. Sharma A, Tran A, Dy M, Najmabadi A, Olazo K, Huang B, Sarkar U. Patient and caregiver perspectives on causes and prevention of ambulatory adverse events: multilingual qualitative study. BMJ Quality & Safety 2024:bmjqs-2023-016955 View
  36. Due A. Is There a “Best” Way for Patients to Participate in Pharmacovigilance?. The Journal of Medicine and Philosophy: A Forum for Bioethics and Philosophy of Medicine 2024 View
  37. Al-Hassany L, Boucherie D, Couturier E, MaassenVanDenBrink A. Author response to ‘Clarification on the incidence and sex-specificity of sexual dysfunction as an adverse event of CGRP-targeting medications’. Cephalalgia 2024;44(10) View

Books/Policy Documents

  1. Gasthuys E, Allegaert K, Degraeuwe E, Nakamura H, Walle J, Kearns G. Essentials of Translational Pediatric Drug Development. View